<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 19, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02015832</url>
  </required_header>
  <id_info>
    <org_study_id>ECRI-002</org_study_id>
    <nct_id>NCT02015832</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate a New Strategy in the Functional Assessment of 3-vessel Disease Using the SYNTAX II Score in Patients Treated With PCI</brief_title>
  <official_title>A Single-arm Trial to Evaluate the Effectiveness of PCI of de Novo 3-vessel Disease Applying the SYNTAX Score II With Pressure Wire Functional Assessment and IVUS Guidance, Using an Everolimus-eluting Stent With Biodegradable Abluminal Coating</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECRI bv</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Volcano Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ECRI bv</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study that aims to evaluate a new strategy using the SYNTAX II Score calculator in
      the functional assessment of patients with new coronary 3-vessel-disease who undergo
      percutaneous coronary intervention (PCI)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the SYNTAX II Trial is to investigate the management of de-novo
      3-vessel-disease in order to prospectively assess which patients would have at least
      comparable short and long term clinical outcomes between coronary artery bypass graft and
      percutaneous coronary intervention (PCI), using contemporary PCI practice. In SYNTAX II the
      effectiveness of a contemporary stent (designed with thinner struts, biocompatible and
      biodegradable polymer, and a limus based drug), the use of pressure wire assessment of
      lesions to allow for ischemia-driven revascularisation, intravascular ultrasound (IVUS)
      guidance to optimise drug eluting stent deployment, and the treatment of (chronic) total
      occlusion lesions with contemporary techniques, will be compared against PCI practice in the
      original SYNTAX trial. The proposed study would involve the SYNTAX Score II to prospectively
      recruit subjects on the grounds of patient safety
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Composite of major adverse cardiac and cerebrovascular events (MACCE) rate compared to PCI arm of SYNTAX I</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause death, cerebrovascular event (stroke), documented myocardial infarction compared to the PCI arm of SYNTAX I</measure>
    <time_frame>1 Year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiovascular death, documented target-vessel myocardial infarction and repeat target lesion revascularization at 1 year follow-up compared to the  PCI arm of SYNTAX I</measure>
    <time_frame>1 Year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of individual components of MACCE at 1 year</measure>
    <time_frame>1 Year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of MACCE and its individual components of 2-5 years period of follow-up (patient reported)</measure>
    <time_frame>2-5 Years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) - according to Universal MI definition 2012</measure>
    <time_frame>1 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis - according to ARC definitions</measure>
    <time_frame>1 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction - according to Universal MI definition 2012</measure>
    <time_frame>2 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction - according to Universal MI definition 2012</measure>
    <time_frame>3 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction - according to Universal MI definition 2012</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction - according to Universal MI definition 2012</measure>
    <time_frame>5 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis - according to ARC definitions</measure>
    <time_frame>2 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis - according to ARC definitions</measure>
    <time_frame>3 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis - according to ARC definitions</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis - according to ARC definitions</measure>
    <time_frame>5 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Composite of MACCE at 5 years follow-up compared to coronary artery bypass graft (CABG) arm of the SYNTAX I Trial</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Exploratory endpoint. MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>3 Vessel Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <description>All patients (single arm study) will be receiving the SYNERGY™ Everolimus eluting stent (EES)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary stent</intervention_name>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <other_name>SYNERGY™ EES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Multi Slice Computed Tomography</intervention_name>
    <description>A coronary non-invasive Multi Slice Computed Tomography will be performed in patients</description>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <other_name>MSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>instantaneous wave-free ratio</intervention_name>
    <description>Pressure-derived, adenosine-free index on physiological assessment of stenosis severity</description>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <other_name>iFR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractional flow reserve</intervention_name>
    <description>Pressure-derived index on physiological assessment of stenosis severity</description>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <other_name>FFR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intravascular Ultrasound</intervention_name>
    <description>Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels</description>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <other_name>IVUS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with de novo 3 vessel disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 1 stenosis, angiographic, visually determined de novo lesions with more than
             50 percent diameter stenosis in all 3 major epicardial territories. These are left
             descending coronary artery (LAD) and or side branch, proximal circumflex coronary
             artery (LCX) and or side branch, right descending coronary artery (RCA) and or side
             branch which are supplying viable myocardium without left main involvement. Patients
             with ostial LAD or ostial CX  Medina 0,0,1 or Medina 0,1,0 may be enrolled

          -  Patients with hypoplastic RCA with absence of descending posterior and presence of a
             lesion in the LAD and CX territories may be included in the trial as a 3 vessel
             disease equivalent

          -  Vessel size should be at least 1.5 mm in diameter as visually assessed in diagnostic
             angiogram

          -  Patients with

               1. stable (Canadian Cardiovascular Society Class 1, 2, 3 or 4) angina pectoris

               2. or unstable (Braunwald class) angina pectoris and ischemia

               3. or patients with atypical chest pain or those who are asymptomatic provided they
                  have myocardial ischemia, for example treadmill exercise test, radionuclide
                  scintigraphy, stress echocardiography

          -  All anatomical SYNTAX Scores are eligible for initial screening with the SYNTAX Score
             II

          -  Patient has been informed of the nature of the study and agrees to its provisions and
             has provided written informed consent as approved by the Ethical Committee of the
             respective clinical site

          -  Signed Heart Team Decision Form between local cardiologist and surgeon that the
             selected case meets all of the inclusion and exclusion criteria

        Exclusion Criteria:

          -  Under the age of 21 years

          -  Known pregnancy at time of enrolment. Female of childbearing potential, and last
             menstruation within the last 12 months, who are not taking adequate contraceptives.
             Female who is breastfeeding at time of enrolment

          -  Prior PCI or CABG

          -  Ongoing acute myocardial infarction and enzymes (CKMB) more than 2x upper limit of
             normal

          -  Concomitant cardiac valve disease requiring surgical therapy, reconstruction or
             replacement

          -  Single or two-vessel disease at time of Heart Team consensus

          -  Participation or planned participation in another cardiovascular clinical study
             before one year follow up is completed

          -  Mental condition, psychiatric or organ cerebral disease, rendering the subject unable
             to understand the nature, scope, and possible consequences of the study or mental
             retardation or language barrier such that the patient is unable to give informed
             consent and potential for non-compliance towards the requirement in the study
             protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Serruys, Prof. MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Thoraxcenter, Erasmus, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Escaned, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Carlos Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrian Banning, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Radcliffe Hospital, Oxford, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerrit-Anne van Es</last_name>
    <role>Study Director</role>
    <affiliation>ECRI, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arie-Pieter Kappetein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thorax center, Erasmus, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Taggart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Radcliffe Hospital, Oxford. United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vasim Farooq, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester Royal Infirmary, United Kingdom</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eliane Lopes Dos Santos</last_name>
    <phone>+31102402409</phone>
    <email>elopes@cardialysis.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rob Schneijdenberg</last_name>
    <phone>+31102062828</phone>
    <email>rschneijdenberg@cardialysis.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Center Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J.J. Piek, MD</last_name>
      <phone>+31 (0) 20 566 9111</phone>
      <email>'j.j.piek@amc.uva.nl'</email>
    </contact>
    <investigator>
      <last_name>J.J. Piek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint-Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maarten Jan Suttorp, MD</last_name>
      <phone>+31 (0)30 609 22 78</phone>
      <email>m.suttorp@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Maarten-Jan Suttorp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ErasmusMC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mattie Lenzen</last_name>
      <phone>+31 (0)10 703 28 91</phone>
      <email>m.lenzen@erasmusmc.nl;</email>
    </contact>
    <contact_backup>
      <last_name>Robert Jan van Geuns, MD</last_name>
      <phone>+31 (0) 10 703 28 91</phone>
      <email>r.vangeuns@erasmusmc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Jan van Geuns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Heart of Poland</name>
      <address>
        <city>Bielsko-Biała</city>
        <zip>43-316</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Turek</last_name>
      <phone>+33 517-262-414</phone>
      <email>a.turek@klinikiserca.pl</email>
    </contact>
    <contact_backup>
      <last_name>Pawel Buszman, MD</last_name>
      <phone>+33 517-262-414</phone>
      <email>pbuszman@ka.onet.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Pawel Buszman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny</name>
      <address>
        <city>Poznan</city>
        <zip>60583</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katarzyna Stanislawska</last_name>
      <phone>0048 606 837 107</phone>
      <email>kasia.stanislawska@onet.eu</email>
    </contact>
    <contact_backup>
      <last_name>Maciej Lesiak, MD</last_name>
      <phone>0048 606 837 107</phone>
      <email>maciej.lesiak@skpp.edu.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Maciej Lesiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Zueco, MD</last_name>
      <phone>0034 9422 027 44</phone>
      <email>jzueco@humv.es</email>
    </contact>
    <investigator>
      <last_name>Javier Zueco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de León</name>
      <address>
        <city>Leon</city>
        <state>Castilla y Leon</state>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Larrode</last_name>
      <phone>0034 987 237 683</phone>
      <email>olarrode@yahoo.es</email>
    </contact>
    <contact_backup>
      <last_name>Amando Perez, MD</last_name>
      <phone>0034 987 237 683</phone>
      <email>aperez@secardiologia.es</email>
    </contact_backup>
    <investigator>
      <last_name>Amando Perez de Prado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Y Provincial</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>8025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Trelliso, researchcoordinator</last_name>
      <phone>0034 9322 793 05</phone>
      <email>etrellis@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>Manel Sabate, MD</last_name>
      <phone>0034 9322 793 05</phone>
      <email>MASABATE@clinic.ub.es</email>
    </contact_backup>
    <investigator>
      <last_name>Manel Sabate, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad Autonoma de Madrid</state>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raul Moreno, MD</last_name>
      <phone>+34 91 727 70 00</phone>
      <phone_ext>47355</phone_ext>
      <email>raulmorenog@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Raul Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad Autonoma de Madrid</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Escaned, MD</last_name>
      <phone>0034 6658 79 441</phone>
      <email>escaned@secardiologia.es</email>
    </contact>
    <investigator>
      <last_name>Javier Escaned, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad Autonoma de Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Antonio Fernandez Diaz</last_name>
      <phone>0034 9119 174 08</phone>
      <email>joseantoniofer@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Javier Goicolea, MD</last_name>
      <phone>0034 9119 174 08</phone>
      <email>j_goicolea@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Javier Goicolea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meixoeiro Hospital</name>
      <address>
        <city>Vigo</city>
        <state>Galicia</state>
        <zip>36214</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seila Diaz Costas</last_name>
      <phone>0034 9868 111 63</phone>
      <email>investigacion.cardioloxia.vigo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Andres Iniguez, MD</last_name>
      <phone>0034 9868 111 63</phone>
      <email>andres.iniguez.romo@sergas.es;</email>
    </contact_backup>
    <investigator>
      <last_name>Andres Iniguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arrixaca University Hospital Murcia</name>
      <address>
        <city>Murcia</city>
        <state>Region de Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariano Valdes, MD</last_name>
      <phone>0034 6296 567 31</phone>
      <email>mvch@valdeschavarri.e.telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Mariano Valdes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignacio Cruz Gonzalez, MD</last_name>
      <phone>0034 6874 256 95</phone>
      <phone_ext>55369</phone_ext>
      <email>cruzgonzalez.ignacio@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ignacio Cruz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Lauriers</last_name>
      <phone>+41 79 55 60 618</phone>
      <email>nathalie.lauriers@chuv.nl</email>
    </contact>
    <contact_backup>
      <last_name>Erik Eeckhout, MD</last_name>
      <phone>+41 79 55 60 618</phone>
      <email>Eric.Eeckhout@chuv.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Erik Eeckhout, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belfast Health &amp; Social Care Trust</name>
      <address>
        <city>Belfast</city>
        <state>County Antrim</state>
        <zip>BT13 1FD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernie Smith</last_name>
      <phone>0044 28 9063 2221</phone>
      <email>bernie.smith@belfasttrust.hscni.net</email>
    </contact>
    <contact_backup>
      <last_name>Simon Walsh, MD</last_name>
      <phone>0044 28 9063 2221</phone>
      <email>simon.walsh@belfasttrust.hscni.net</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Walsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Infirmary Oxford II</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Moreby, study coordinator</last_name>
      <phone>+44 (0) 1865</phone>
      <email>bernadette.moreby@ouh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Adrian Banning, MD</last_name>
      <phone>+44 1865 22 89 34</phone>
      <email>adrian.banning@ouh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Adrian Banning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital, Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sallyanne Meakins</last_name>
      <phone>+44 01480 364980</phone>
      <email>Sallyanne.meakins@papworth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Nick West, MD</last_name>
      <phone>+44 01480 364504</phone>
      <email>Nick.West@papworth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Nick West, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Belinda Rif, study coordinator</last_name>
      <phone>+44  0131 242 1886</phone>
      <email>belinda.rif@nhslothian.scot.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Neal Uren, MD</last_name>
      <phone>+44  0131 242 1046</phone>
      <email>neal.uren@nhslothian.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Neal Uren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Appleby, MD</last_name>
      <phone>+44 01510600 1887</phone>
      <email>Clare.Appleby@lhch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Clare Appleby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rasha Al-Lamee</last_name>
      <phone>0044 797 183 1328</phone>
      <email>&quot;Rasha.Al-Lamee@imperial.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Justin Davies, MD</last_name>
      <phone>0044 797 183 1328</phone>
      <email>justindavies@heart123.com</email>
    </contact_backup>
    <investigator>
      <last_name>Justin Davies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jayne Damm</last_name>
      <phone>+44 20 7188 9484</phone>
      <email>jayne.damm@gsstt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Simon Redwood, MD</last_name>
      <phone>+44 0207 1888 6271</phone>
      <email>simon.redwood@gstt.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Redwood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The London Chest Hospital</name>
      <address>
        <city>London</city>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessry Veerapen</last_name>
      <phone>+44 (0)208 983 2213</phone>
      <email>dj.veerapen@bartshealth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Charles Knight, MD</last_name>
      <phone>+44 (0)208 983 2213</phone>
      <email>charles.knight@bartsandthelondon.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Knight, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Evans</last_name>
      <phone>+44 (0) 161 276 3336</phone>
      <email>Sarah.evansmhc@cmft.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Faz Fath Ordoubadi, MD</last_name>
      <phone>+44 (0) 161 276 5770</phone>
      <email>Farzin.Fath-ordoubadi@cmft.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Faz Fath Ordoubadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samantha Jones</last_name>
      <phone>+44 (0)191 2138272</phone>
      <email>samantha.jones@nuth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Azfar Zaman, MD</last_name>
      <phone>+44 (0)191 213 72 77</phone>
      <email>azfar.zaman@nuth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Azfar Zaman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>December 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SYNTAX II Score</keyword>
  <keyword>Pressure wires</keyword>
  <keyword>instantaneous wave-free ratio</keyword>
  <keyword>fractional flow reserve</keyword>
  <keyword>intravascular ultrasound</keyword>
  <keyword>Drug eluting stents</keyword>
  <keyword>Stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>multi slice computed tomography</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
